Small Cell Lung Cancer Clinical Trial
Official title:
FLT-PET for Early Detection of Relapse in Patients With Irradiated Lung Cancer
| NCT number | NCT02995889 |
| Other study ID # | 308_14 |
| Secondary ID | |
| Status | Completed |
| Phase | N/A |
| First received | |
| Last updated | |
| Start date | November 2014 |
| Est. completion date | February 7, 2020 |
| Verified date | May 2022 |
| Source | Rigshospitalet, Denmark |
| Contact | n/a |
| Is FDA regulated | No |
| Health authority | |
| Study type | Interventional |
This study investigates the feasibility of FLT-PET to improve the diagnosis of relapse in patients with irradiated lung cancer in comparison with FDG-PET/CT.
| Status | Completed |
| Enrollment | 64 |
| Est. completion date | February 7, 2020 |
| Est. primary completion date | February 7, 2019 |
| Accepts healthy volunteers | No |
| Gender | All |
| Age group | 18 Years and older |
| Eligibility | Inclusion Criteria: - history with lung cancer, small cell or non-small cell - radiotherapy of lung cancer ended within the last 24 months - radiotherapy might be normofractionated or stereotactic - current suspicion of relapse - written and oral consent Exclusion Criteria: - communication difficulties - pregnancy or lactation |
| Country | Name | City | State |
|---|---|---|---|
| Denmark | Dept. of Clinical Physiology, Nuclear Medicine and PET, Rigshospitalet | Copenhagen | |
| Denmark | Dept. Respiratory Medicine, Bispebjerg University Hospital | Copenhagen |
| Lead Sponsor | Collaborator |
|---|---|
| Rigshospitalet, Denmark |
Denmark,
Christensen TN, Langer SW, Persson G, Larsen KR, Amtoft AG, Keller SH, Kjaer A, Fischer BM. Impact of [(18)F]FDG-PET and [(18)F]FLT-PET-Parameters in Patients with Suspected Relapse of Irradiated Lung Cancer. Diagnostics (Basel). 2021 Feb 11;11(2). pii: 2 — View Citation
Christensen TN, Langer SW, Persson G, Larsen KR, Loft A, Amtoft AG, Berthelsen AK, Johannesen HH, Keller SH, Kjaer A, Fischer BM. (18)F-FLT PET/CT Adds Value to (18)F-FDG PET/CT for Diagnosing Relapse After Definitive Radiotherapy in Patients with Lung Ca — View Citation
| Type | Measure | Description | Time frame | Safety issue |
|---|---|---|---|---|
| Primary | Number of patients with local and/or regional relapse | 6 months |
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Not yet recruiting |
NCT03651219 -
Mesylate Apatinib Combined With Irinotecan in Treatment of Recurrent Small Cell Lung Cancer
|
Phase 3 | |
| Active, not recruiting |
NCT03958045 -
Combination Rucaparib With Nivolumab in Small Cell Lung Carcinoma
|
Phase 2 | |
| Completed |
NCT04381910 -
Irinotecan Hydrochloride Liposome Injection (LY01610) For Small Cell Lung Cancer
|
Phase 2 | |
| Active, not recruiting |
NCT04885998 -
AMG 757 and AMG 404 in Subjects With Small Cell Lung Cancer (SCLC)
|
Phase 1 | |
| Active, not recruiting |
NCT03703297 -
Study of Durvalumab + Tremelimumab, Durvalumab, and Placebo in Limited Stage Small-Cell Lung Cancer in Patients Who Have Not Progressed Following Concurrent Chemoradiation Therapy
|
Phase 3 | |
| Recruiting |
NCT05903092 -
MOnaliZumab in Combination With durvAlumab (MEDI4736) Plus Platinum-based chemotheRapy for First-line Treatment of Extensive Stage Small Cell Lung Cancer
|
Phase 2 | |
| Completed |
NCT03652077 -
A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies
|
Phase 1 | |
| Terminated |
NCT04422210 -
A Study Evaluating The Safety, Tolerability, Pharmacokinetics, And Efficacy Of Venetoclax In Combination With Atezolizumab, Carboplatin, And Etoposide In Participants With Untreated Extensive-Stage Small Cell Lung Cancer (ES-SCLC).
|
Phase 1 | |
| Not yet recruiting |
NCT02875457 -
Apatinib as the Maintenance Therapy for Extensive Stage Small Cell Lung Cancer After Combined With Etoposide/Cisplatin
|
Phase 3 | |
| Recruiting |
NCT02577627 -
Multi-Indication, Retrospective Oncological Study to Validate the Accuracy in Predicting TTP by PrediCare in Patients Under SOC
|
N/A | |
| Recruiting |
NCT02605811 -
Temozolomide in Preventing Brain Metastases in Small Cell Lung Cancer
|
Phase 2 | |
| Withdrawn |
NCT02542137 -
Abscopal Effect for Metastatic Small Cell Lung Cancer
|
Phase 2 | |
| Completed |
NCT02551432 -
Pembrolizumab and Paclitaxel in Refractory Small Cell Lung Cancer
|
Phase 2 | |
| Recruiting |
NCT02262897 -
The Efficacy and Safety of Nab-paclitaxel in Pretreated Patients With Extensive Disease of Small Cell Lung Cancer
|
Phase 2 | |
| Completed |
NCT01831089 -
Phase I Study of Lurbinectedin (PM01183) in Combination With Paclitaxel, With or Without Bevacizumab, in Selected Advanced Solid Tumors
|
Phase 1 | |
| Terminated |
NCT00969306 -
Chloroquine as an Anti-Autophagy Drug in Stage IV Small Cell Lung Cancer (SCLC) Patients
|
Phase 1 | |
| Completed |
NCT01943578 -
Value of Physical Capacity Tests in Lung Cancer
|
N/A | |
| Completed |
NCT01497873 -
A Randomized Study to Compare the Efficacy and Safety of Belotecan and Topotecan as Monotherapy for Sensitive-Relapsed Small Cell Lung Cancer
|
Phase 2 | |
| Terminated |
NCT00958022 -
Carboplatin and Etoposide Plus LBH589 for Small Cell Lung Cancer
|
Phase 1 | |
| Completed |
NCT00930891 -
Bevacizumab in Extensive Small Cell Lung Cancer
|
Phase 2/Phase 3 |